Trial Profile

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Opnurasib (Primary) ; Batoprotafib; Cetuximab; Tislelizumab; Trametinib
Indications Non-small cell lung cancer; Solid tumours
Focus Therapeutic Use
Acronyms KontRASt-R
Sponsors Novartis

02 Apr 2026 Planned End Date changed from 25 Sep 2029 to 17 Sep 2029.
02 Apr 2026 Planned primary completion date changed from 25 Jun 2029 to 15 Jun 2029.
02 Apr 2026 Planned initiation date changed from 24 Jun 2026 to 15 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com